Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
H3N2 Infection - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H1 2016', provides an overview of the H3N2 Infection pipeline landscape. The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of H3N2 Infection - The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects - The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for H3N2 Infection Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for H3N2 Infection - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 H3N2 Infection Overview 10 Therapeutics Development 11 Pipeline Products for H3N2 Infection - Overview 11 Pipeline Products for H3N2 Infection - Comparative Analysis 12 H3N2 Infection - Therapeutics under Development by Companies 13 H3N2 Infection - Therapeutics under Investigation by Universities/Institutes 15 H3N2 Infection - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 H3N2 Infection - Products under Development by Companies 19 H3N2 Infection - Products under Investigation by Universities/Institutes 21 H3N2 Infection - Companies Involved in Therapeutics Development 22 AIMM Therapeutics B.V. 22 Aphios Corporation 23 Crucell N.V. 24 CSL Limited 25 Glide Pharmaceutical Technologies Limited 26 ILiAD Biotechnologies, LLC 27 Inovio Pharmaceuticals, Inc. 28 Johnson & Johnson 29 Medicago Inc. 30 MedImmune, LLC 31 Mucosis B.V. 32 NanoViricides, Inc. 33 Novavax, Inc. 34 OPKO Health, Inc. 35 Sarepta Therapeutics, Inc. 36 Takeda Pharmaceutical Company Limited 37 Visterra, Inc. 38 Zydus Cadila Healthcare Limited 39 H3N2 Infection - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 APP-0205 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 APP-309 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Aspidasept - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 C-05 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 CR-8020 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CR-9114 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 FluGEM - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Gamma-Flu - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 influenza [strain A/H3N2] vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 influenza [strain A/H3N2] vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 JNJ-872 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NVINF-1 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NVINF-2 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pertussis [strain BPZE1] vaccine - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PNSIA-28 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 radavirsen - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules for RSV and Influenza A Infections - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 TXB-248 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 VIS-410 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 H3N2 Infection - Recent Pipeline Updates 90 H3N2 Infection - Dormant Projects 103 H3N2 Infection - Product Development Milestones 104 Featured News & Press Releases 104 Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 104 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107
List of Tables Number of Products under Development for H3N2 Infection, H1 2016 11 Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016 22 H3N2 Infection - Pipeline by Aphios Corporation, H1 2016 23 H3N2 Infection - Pipeline by Crucell N.V., H1 2016 24 H3N2 Infection - Pipeline by CSL Limited, H1 2016 25 H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 26 H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 27 H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 28 H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016 29 H3N2 Infection - Pipeline by Medicago Inc., H1 2016 30 H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016 31 H3N2 Infection - Pipeline by Mucosis B.V., H1 2016 32 H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016 33 H3N2 Infection - Pipeline by Novavax, Inc., H1 2016 34 H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016 35 H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016 36 H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37 H3N2 Infection - Pipeline by Visterra, Inc., H1 2016 38 H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 39 Assessment by Monotherapy Products, H1 2016 40 Assessment by Combination Products, H1 2016 41 Number of Products by Stage and Target, H1 2016 43 Number of Products by Stage and Mechanism of Action, H1 2016 45 Number of Products by Stage and Route of Administration, H1 2016 47 Number of Products by Stage and Molecule Type, H1 2016 49 H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016 90 H3N2 Infection - Dormant Projects, H1 2016 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
